149 related articles for article (PubMed ID: 9225779)
1. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
2. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.
Kostakoglu L; Kiratli P; Ruacan S; Hayran M; Emri S; Ergün EL; Bekdik CF
J Nucl Med; 1998 Feb; 39(2):228-34. PubMed ID: 9476923
[TBL] [Abstract][Full Text] [Related]
3. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer.
Kostakoglu L; Ruacan S; Ergün EL; Sayek I; Elahi N; Bekdik CF
J Nucl Med; 1998 Jun; 39(6):1021-6. PubMed ID: 9627337
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
Sergieva SB; Timcheva KV; Hadjiolov ND
J BUON; 2006; 11(1):61-8. PubMed ID: 17318954
[TBL] [Abstract][Full Text] [Related]
6. The value of Tc-99m tetrofosmin scintimammography in the assessment of P-glycoprotein in patients with breast cancer.
Silov G; Erdoğan Z; Özdal A; Tutuş A; Tekin Y; Karaman H; Turhal Ö
Hell J Nucl Med; 2013; 16(3):218-22. PubMed ID: 24137583
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
9. Expression of drug resistance protein related to Tc-99m MIBI breast imaging.
Sun SS; Hsieh JF; Tsai SC; Ho YJ; Kao CH
Anticancer Res; 2000; 20(3B):2021-5. PubMed ID: 10928145
[TBL] [Abstract][Full Text] [Related]
10. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
11. Quantified 99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients: factors that influence the level of 99m Tc-MIBI uptake.
Fuster D; Muñoz M; Pavia J; Palacín A; Bellet N; Mateos JJ; Martín F; Ortega M; Setoain FJ; Pons F
Nucl Med Commun; 2002 Jan; 23(1):31-8. PubMed ID: 11748435
[TBL] [Abstract][Full Text] [Related]
12. P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings.
Kao CH; Tsai SC; Liu TJ; Ho YJ; Wang JJ; Ho ST; ChangLai SP
Cancer Res; 2001 Feb; 61(4):1412-4. PubMed ID: 11245443
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression.
Kao A; Shiun SC; Hsu NY; Sun SS; Lee CC; Lin CC
Ann Oncol; 2001 Nov; 12(11):1561-6. PubMed ID: 11822755
[TBL] [Abstract][Full Text] [Related]
14. Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression.
Chang CS; Yang SS; Yeh HZ; Kao CH; Chen GH
Hepatogastroenterology; 2004; 51(55):211-4. PubMed ID: 15011866
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
Kawata K; Kanai M; Sasada T; Iwata S; Yamamoto N; Takabayashi A
Clin Cancer Res; 2004 Jun; 10(11):3788-93. PubMed ID: 15173086
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
17. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
18. Using technetium-99m tetrofosmin chest imaging to predict taxol-based chemotherapy response in non-small cell lung cancer but not related to lung resistance protein expression.
Shih CM; Shiau YC; Wang JJ; Ho ST; Kao A
Lung; 2003; 181(2):103-11. PubMed ID: 12953149
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability.
Bhatnagar A; Vezza PR; Bryan JA; Atkins FB; Ziessman HA
J Nucl Med; 1998 Sep; 39(9):1617-20. PubMed ID: 9744355
[TBL] [Abstract][Full Text] [Related]
20. To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with p-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression.
Kuo TH; Liu FY; Chuang CY; Wu HS; Wang JJ; Kao A
Nucl Med Biol; 2003 Aug; 30(6):627-32. PubMed ID: 12900288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
